KaydedilenlerDerginizi ekleyin

Dergiler / Journal of Clinical and Experimental Investigations / 2015 / Cilt: 6 Sayı: 4

Evaluation of the metabolic characteristics of patients with Acromegaly

Faruk Kılınç
Zafer Pekkolay
Nevzat Gözel
Hikmet Soylu
Ahmet Yılmaz
Yaşar Yıldırım
Fatih Şahpaz
Alpaslan Tuzcu
Sayfa
382–386
Yayın Tarihi
2016-01-03
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

J Clin Exp Invest 2015; 6 (4): 382-386 Key words: Acromegaly, hypertension, diabetes

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Acromegaly is a syndrome characterized by growth hormone (GH) and insulin like growth factor-1 (IGF-1) over secretion.
📊
Temel Bulgular & Veri:Methods: One hundred five patients, who were diagnosed as acromegaly in our clinic between 2010 and 2015, were enrolled to the study.
💡
Sonuç & Katkı:J Clin Exp Invest 2015; 6 (4): 382-386 Key words: Acromegaly, hypertension, diabetes
🔬Tür:Makale
📍Kapsam:2010 Verileri
⚙️Değişkenler:Akromegali · hipertansiyon · diyabet

Özet

Objective: Acromegaly is a syndrome characterized by growth hormone (GH) and insulin like growth factor-1 (IGF-1) over secretion. It was aimed to sharing detected metabolic disorders of the patients with acromegaly who have been under follow-up at our clinic. Methods: One hundred five patients, who were diagnosed as acromegaly in our clinic between 2010 and 2015, were enrolled to the study. The age, gender, involvement feature additional systemic and metabolic diseases were recorded and laboratory findings. Results: A total of 105 patients included in the study, 56 women (53.3%) and 49 men (46.7%), respectively. Patient’s’ ages ranged 23-78 (mean 42.1±16.7). 34 patients (32.3%), hypertension in 20 (19.04%), diabetes mellitus, and is 11 (10.4%) had impaired glucose tolerance. Conclusion: Somatic disfigurement (hand and foot enlargement etc.) is the major characteristic of the disease but the prognosis is determined by cardiovascular, respiratory and metabolic complications. In acromegaly, hypertension and diabetes are common, cardiovascular disease is the principal cause of death. We believe that our study will contribute to the determination of our country’s data. J Clin Exp Invest 2015; 6 (4): 382-386 Key words: Acromegaly, hypertension, diabetes

🔖

Bu Makaleye Atıf Yap

Kılınç, F., Pekkolay, Z., Gözel, N., Soylu, H., Yılmaz, A., Yıldırım, Y., Şahpaz, F., Tuzcu, A. (2016). Evaluation of the metabolic characteristics of patients with Acromegaly. Journal of Clinical and Experimental Investigations, Cilt: 6 Sayı: 4, 382–386. https://doi.org/10.5799/ahinjs.01.2015.04.0553

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (28)

  1. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006;355:2558-2565.
  2. Thorner MO, LeeVance M, Laws ER Jr, et al. The anterior
  3. pituitary. W Textbook of Endocrinol 1998;128:249-340.
  4. Acromegaly: Epidemiology, etiology and classification in: Acromegaly and its management In: Haris AG. Lipp Raven NY 1996;22:17-20.
  5. Ho KY, WeisSberger AJ. Characterisation of 24 hour GH secretion in acromegaly: Implications for diagnosis and therapy. Clin Endocrinol 1994;41:75-83.
  6. Baumann G. Growth hormone and its disorders. I: Principles
  7. and Practices of Endocrinology and Metabolism, In: Becker KL, ed. Lipincott Williams & Wilkins 2001;20:129-145.
  8. Melmed S. Acromegaly. NEJM 1990;322:966-977.
  9. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.J Clin Endocrinol Metab 2005;90:5684-5691.
  10. Parkinson C, Drake WM, Wieringa G, et al. Serum lipoprotein
  11. changes following IGF-1 normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol 2002;56:303-311.
  12. Tan KC, Shiu SW, Janus ED, et al. Subfractions in acromegaly:
  13. relation to growth hormone and insulin-like growth factor-I. Atherosclerosis 1997;129:59-65.
  14. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot longacting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000;85:3132-3140.
  15. Colao A, Vitale G, Pivonello R, et al. The heart: an end-organ of GH action. Eur J Endocrinol 2004;15:93-101.
  16. Mestron A, Webb SM, Astorga R, et al. Epidemiology,clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004;151:439-446.
  17. Hekimsoy Z, Özmen B. Acromegali. Turk J Endocrinol Metabol 2003;7:69-75.
  18. Chen YL, Wei CP, Lee CC, Chang TC. Diabetic ketoacidosis
  19. in a patient with acromegaly. J Formos Med Assoc 2007;106:788-791.
  20. Smith TR, Elmendorf JS, David TS. Growth hormone-induced
  21. insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4. Am J Physiol 1997;272:1071-1080.
  22. Hekimsoy Z, Ozmen B, Ulusoy S. Homocysteine levels in acromegaly patients. Neuro Endocrinol Lett 2005;26:811-814.
  23. Ronconi V, Giacchetti G, Mariniello B, et al. Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press 2005;14:227-232.
  24. Absoch A, Tyrrell JB, Lamborn KR, et al. Transsphonidal
  25. microsurgery for growth hormone-secreting pituitary adenomasinitial outcome and long-term results. J Clin Endocrinol Metab 1998;83:3411-3418.
  26. Melmed S. Acromegaly and cancer: not a problem. J Clin Endocrinol Metab 2001;86:2929-2934.20. Sacca AL, Cittadini A, Fazio S. Growth hormone and the heart. Endocrine Rev 1994;15:555-572.
  27. Nabarro JDN. Acromegaly. Clin Endocrinol 1987;26:481-512.
  28. Lam KS, Pang RW, Janus ED, et al. Serum apolipoprotein (a) correlates with groth hormone levels in Chinese patients with acromegaly. Atherosclerosis 1993;104:183-188.